1. Prospective Single Arm Study on the Effect of Ilaprazole in Patients with Heartburn but No Reflux Esophagitis
- Author
-
Hyunki Kim, In Ji Song, Na Keum Lee, and Sang Kil Lee
- Subjects
Adult ,medicine.medical_specialty ,Esophageal pH Monitoring ,reflux esophagitis ,Gastroenterology ,2-Pyridinylmethylsulfinylbenzimidazoles ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Heartburn ,Internal medicine ,Surveys and Questionnaires ,medicine ,Electric Impedance ,Humans ,In patient ,Prospective Studies ,Reflux esophagitis ,Esophagus ,Prospective cohort study ,Aged ,Gastroenterology & Hepatology ,Ilaprazole ,business.industry ,ilaprazole ,Reflux ,Endoscopy ,Proton Pump Inhibitors ,General Medicine ,Middle Aged ,medicine.disease ,medicine.anatomical_structure ,chemistry ,030220 oncology & carcinogenesis ,030211 gastroenterology & hepatology ,Original Article ,Female ,medicine.symptom ,business ,Esophagitis - Abstract
PURPOSE Patients with gastroesophageal reflux disease without esophagitis show varying responses to proton pump inhibitors (PPIs). The aim of this study was to objectively evaluate the effect of a new PPI, ilaprazole, on patients with heartburn but without reflux esophagitis. MATERIALS AND METHODS This prospective study was performed on 20 patients with heartburn but without reflux esophagitis. All patients underwent upper endoscopy and 24-hr combined multichannel intraluminal impedance and pH esophageal monitoring (MII-pH). They were then treated with ilaprazole (20 mg) once daily for 4 weeks. The GerdQ questionnaire, histologic findings, and inflammatory biomarkers were used for assessment before and after ilaprazole. RESULTS Among the 20 patients, 13 (65%) showed GerdQ score ≥8. Based on MII-pH results, patients were classified as true nonerosive reflux disease (n=2), hypersensitive esophagus (n=10), and functional heartburn (n=8). After treatment, patients showed a statistically significant improvement in GerdQ score (p
- Published
- 2018